LeapFinancial | $3,500,000 | (Dec 20, 2024)
TG0 | $5,619,170 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
HotSpot Therapeutics, Inc.
United States
- Boston, Massachusetts
- 29/11/2021
- Series C
- $100,000,000
Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.
HotSpot is supported by a syndicate of leading healthcare investors based in the US and Europe.
- Industry Biotechnology Research
- Website https://www.hotspotthera.com/
- LinkedIn https://www.linkedin.com/company/hotspot-therapeutics/about/
Related People
Jonathan MontaguFounder
United States -
Cambridge, Massachusetts
Previous experience in startup Operations, Business Development, pharmaceutical Marketing and New Product Development in biotech and big pharma setting. Former management consultant with training as synthetic organic chemist. 12 years based in Cambridge, MA and San Francisco, CA. Now based in Boston and Berlin, Germany.
HOTSPOT THERAPEUTICS
• President & Chief Executive Officer
EPIIOS THERAPEUTICS
• Chief Executive Officer & Managing Director
NIMBUS THERAPEUTICS
* Responsible for Business Development, Finance, Legal, Operations, IT reporting to Chairman of Board
* Completed $42MM Series A financing led by Atlas Venture, SR One, Lilly Ventures, Gates Ventures
* Transactions with Shire, Schrödinger, Monsanto, Genentech.
ATLAS VENTURE – Executive-in-Residence
CONCERT PHARMACEUTICALS
* Responsible for out-licensing efforts around lead programs (anti-infectives, diabetes, anti-fibrotic) and non-traditional BD including animal health, foundations, federal funding and API manufacturing
* Driving New Product Development activities including target product profile development, forecasting, portfolio prioritization, business case development across multiple programs and disease indications
ORTHO-McNEIL PHARMACEUTICALS
* New Product Development Manager for US launch of doripenem and ceftobiprole, two anti-infective products
STANFORD GRADUATE SCHOOL OF BUSINESS
BIOGEN IDEC: Associate, Business Development
CHIRON CORPORATION: Special Advisor
* Program Leader, BioPharma Research Strategy
* Project Co-Lead, Chiron Manufacturing Initiative (CMI)
BOSTON CONSULTING GROUP: Consultant
* Post-merger integration for multinational pharma company
* IP-licensing strategy for a $10B research funding organization
Research experience
* The Scripps Research Institute
* Cold Spring Harbor Laboratory
* Imperial Cancer Research Fund
* Oxford University Dyson Perrins Laboratory
ŌURA | $200,000,000 | (Dec 20, 2024)
Buildpeer | $2,500,000 | (Dec 20, 2024)
Embeddable | $6,238,050 | (Dec 20, 2024)
Tenor | $5,400,000 | (Dec 20, 2024)
SOTELIX Endoscopy | $1,700,000 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
TripSuite | $5,000,000 | (Dec 20, 2024)
Seekho | $8,000,000 | (Dec 19, 2024)